171 related articles for article (PubMed ID: 15238559)
1. Carmustine, vincristine, and prednisone in the treatment of canine lymphosarcoma.
Ricci Lucas SR; Pereira Coelho BM; Marquezi ML; Franchini ML; Miyashiro SI; De Benedetto Pozzi DH
J Am Anim Hosp Assoc; 2004; 40(4):292-9. PubMed ID: 15238559
[TBL] [Abstract][Full Text] [Related]
2. Pilot clinical study of carmustine associated with a lipid nanoemulsion in combination with vincristine and prednisone for the treatment of canine lymphoma.
Lucas SR; Maranhão RC; Guerra JL; Coelho BM; Barboza R; Pozzi DH
Vet Comp Oncol; 2015 Sep; 13(3):184-93. PubMed ID: 23615221
[TBL] [Abstract][Full Text] [Related]
3. Lomustine and prednisone as a first-line treatment for dogs with multicentric lymphoma: 17 cases (2004-2005).
Sauerbrey ML; Mullins MN; Bannink EO; Van Dorp TE; Kaneene JB; Obradovich JE
J Am Vet Med Assoc; 2007 Jun; 230(12):1866-9. PubMed ID: 17571992
[TBL] [Abstract][Full Text] [Related]
4. Retrospective analysis for treatment of naïve canine multicentric lymphoma with a 15-week, maintenance-free CHOP protocol.
Curran K; Thamm DH
Vet Comp Oncol; 2016 Aug; 14 Suppl 1():147-55. PubMed ID: 26279153
[TBL] [Abstract][Full Text] [Related]
5. Chemotherapy for canine lymphosarcoma.
Madewell BR
Am J Vet Res; 1975 Oct; 36(10):1525-8. PubMed ID: 1242622
[TBL] [Abstract][Full Text] [Related]
6. Chemotherapy-induced neutropenia is associated with prolonged remission duration and survival time in canine lymphoma.
Wang SL; Lee JJ; Liao AT
Vet J; 2015 Jul; 205(1):69-73. PubMed ID: 26004824
[TBL] [Abstract][Full Text] [Related]
7. A phase II study to evaluate the toxicity and efficacy of alternating CCNU and high-dose vinblastine and prednisone (CVP) for treatment of dogs with high-grade, metastatic or nonresectable mast cell tumours.
Rassnick KM; Bailey DB; Russell DS; Flory AB; Kiselow MA; Intile JL; Malone EK; Balkman CE; Barnard SM
Vet Comp Oncol; 2010 Jun; 8(2):138-52. PubMed ID: 20579327
[TBL] [Abstract][Full Text] [Related]
8. Chemotherapeutic responses in dogs with lymphosarcoma and hypercalcemia.
Weller RE; Theilen GH; Madewell BR
J Am Vet Med Assoc; 1982 Nov; 181(9):891-3. PubMed ID: 6897239
[TBL] [Abstract][Full Text] [Related]
9. Randomized controlled trial of doxorubicin versus dactinomycin in a multiagent protocol for treatment of dogs with malignant lymphoma.
Khanna C; Lund EM; Redic KA; Hayden DW; Bell FW; Goulland EL; Klausner JS
J Am Vet Med Assoc; 1998 Oct; 213(7):985-90. PubMed ID: 9776993
[TBL] [Abstract][Full Text] [Related]
10. Mechlorethamine, procarbazine and prednisone for the treatment of resistant lymphoma in dogs.
Northrup NC; Gieger TL; Kosarek CE; Saba CF; LeRoy BE; Wall TM; Hume KR; Childress MO; Keys DA
Vet Comp Oncol; 2009 Mar; 7(1):38-44. PubMed ID: 19222829
[TBL] [Abstract][Full Text] [Related]
11. Assessment of potential doubling time (Tpot), argyrophilic nucleolar organizer regions (AgNOR), and proliferating cell nuclear antigen (PCNA) as predictors of therapy response in canine non-Hodgkin's lymphoma.
Vail DM; Kisseberth WC; Obradovich JE; Moore FM; London CA; MacEwen EG; Ritter MA
Exp Hematol; 1996 Jun; 24(7):807-15. PubMed ID: 8647231
[TBL] [Abstract][Full Text] [Related]
12. Cyclic combination chemotherapy of canine lymphosarcoma.
MacEwen EG; Brown NO; Patnaik AK; Hayes AA; Passe S
J Am Vet Med Assoc; 1981 Jun; 178(11):1178-81. PubMed ID: 6895078
[No Abstract] [Full Text] [Related]
13. Prognostic variables in canine multicentric lymphosarcoma.
Dobson JM; Blackwood LB; McInnes EF; Bostock DE; Nicholls P; Hoather TM; Tom BD
J Small Anim Pract; 2001 Aug; 42(8):377-84. PubMed ID: 11518416
[TBL] [Abstract][Full Text] [Related]
14. Chlorambucil and prednisolone chemotherapy for dogs with inoperable mast cell tumours: 21 cases.
Taylor F; Gear R; Hoather T; Dobson J
J Small Anim Pract; 2009 Jun; 50(6):284-9. PubMed ID: 19527421
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and toxicity of doxorubicin/cyclophosphamide maintenance therapy in dogs with multicentric lymphosarcoma.
Price GS; Page RL; Fischer BM; Levine JF; Gerig TM
J Vet Intern Med; 1991; 5(5):259-62. PubMed ID: 1748977
[TBL] [Abstract][Full Text] [Related]
16. Doxorubicin alone or in combination with asparaginase, followed by cyclophosphamide, vincristine, and prednisone for treatment of multicentric lymphoma in dogs: 121 cases (1987-1995).
Valerius KD; Ogilvie GK; Mallinckrodt CH; Getzy DM
J Am Vet Med Assoc; 1997 Feb; 210(4):512-6. PubMed ID: 9040837
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of a multi-agent chemotherapy protocol combining dexamethasone, melphalan, actinomycin D, and cytarabine for the treatment of resistant canine non-Hodgkin high-grade lymphomas: a single centre's experience.
Smallwood K; Tanis JB; Grant IA; Blackwood L; Killick DR; Amores-Fuster I; Elliott J; Mas A; Harper A; Marrington M; Finotello R
Vet Comp Oncol; 2019 Jun; 17(2):165-173. PubMed ID: 30666777
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of some prognostic factors for advanced multicentric lymphosarcoma in the dog: 147 cases (1978-1981).
MacEwen EG; Hayes AA; Matus RE; Kurzman I
J Am Vet Med Assoc; 1987 Mar; 190(5):564-8. PubMed ID: 3558097
[TBL] [Abstract][Full Text] [Related]
19. Lymphosarcoma. A comparison of extended to conservative chemotherapy.
Kaufman JH; Ezdinli E; Aungst CW; Stutzman L
Cancer; 1976 Mar; 37(3):1283-92. PubMed ID: 946592
[TBL] [Abstract][Full Text] [Related]
20. Histologic classification as a prognostic criterion for canine lymphosarcoma.
Weller RE; Holmberg CA; Theilen GH; Madewell BR
Am J Vet Res; 1980 Aug; 41(8):1310-4. PubMed ID: 6893792
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
